MultiCASE Inc.

Beachwood,  OH 
United States
http://www.multicase.com

In silico toxicity predictions used for ICH M7 and REACH.

MultiCASE develops computer programs and QSAR models designed to assess the potential pharmacological activity, toxicity, and metabolic transformation of new chemicals; some of which are a result of the long-standing research collaboration between the company and the US FDA.

The in silico testing available through MultiCASE provides a unique range of toxicological assessments, including bacterial mutagenicity for ICH M7 using both statistical and expert rule-based (Q)SAR methodologies; assessing carcinogenic potency of nitrosamines using novel analog search methodologies; predicting xenobiotic metabolites; skin senitization EC3 categorical testing, among others.

These computational approaches offer the advantage of screening large quantities of chemicals without the use of animal testing, and potentially revealing novel chemo-biological mechanisms.  

The models follow OECD guidelines and can also be used to satisfy the information requirements listed in REACH.